ArticleScience signaling2018
Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
Article in Science signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 73 citations in OpenAlex.
- Mapping the TNFR2-targeting antibody patent landscape: Insights from macro trends to structural signatures.Human vaccines & immunotherapeutics · 2026Article
- Tumor-Infiltrating mregDCs Restrain Anti-Tumor Immunity in Early Relapse HCC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- 3M-052 combined inhibitory anti-TNFR2 synergistically suppresses colon cancer progression.Frontiers in immunology · 2026Article
- TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8Oncoimmunology · 2025Article
- H3K18 lactylation in cancer-associated fibroblasts drives malignant pleural effusion progression via TNFR2Experimental & molecular medicine · 2025Article
- Regulatory T cells in cancer anti-PD-(L)1 therapy.Human cell · 2025Review
- The Role of Tregs in the Tumor Microenvironment.Biomedicines · 2025Review
- Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.Journal of experimental & clinical cancer research : CR · 2024Review
- TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.Journal for immunotherapy of cancer · 2024Article
- Targeting TNFR2 for cancer immunotherapy: recent advances and future directions.Journal of translational medicine · 2024Review
- Review
- Review
- Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer.Research (Washington, D.C.) · 2024Article
- TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4Cellular oncology (Dordrecht, Netherlands) · 2023Article
- TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.Frontiers in immunology · 2023Article
- Cytokines and Hepatocellular Carcinoma: Biomarkers of a Deadly Embrace.Journal of personalized medicine · 2022Review
- TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2022Review
- Review
- Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.MedComm · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
Abstract
Through the tumor necrosis factor (TNF) receptor type II (TNFR2), TNF preferentially activates, expands, and promotes the phenotypic stability of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.